DHR
61
5
CTAS
64
3
AMG
55
3
WBA
35
-3
ROP
71
6
IR
85
5
SYK
60
7
KLAC
71
4
CHK
41
2
MCD
50
3
WYNN
38
-2
WM
77
-5
VRSK
75
-2
ICE
69
3
GME
88
-10
TRV
45
-4
JCI
44
3
MDLZ
51
-2
ES
41
2
JWN
73
-3
DHR
61
5
CTAS
64
3
AMG
55
3
WBA
35
-3
ROP
71
6
IR
85
5
SYK
60
7
KLAC
71
4
CHK
41
2
MCD
50
3
WYNN
38
-2
WM
77
-5
VRSK
75
-2
ICE
69
3
GME
88
-10
TRV
45
-4
JCI
44
3
MDLZ
51
-2
ES
41
2
JWN
73
-3
Financhill
Back

Y-mAbs Therapeutics 10K Form

Sell
39

YMAB
Y-mAbs Therapeutics

Last Price:
12.04
Seasonality Move:
11.04%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive YMAB News And Ratings

See the #1 stock for the next 7 days that we like better than YMAB

YMAB Financial Statistics

Sales & Book Value

Annual Sales: $84.82M
Cash Flow: $-3.48M
Price / Cash Flow: 0
Annual Sales: $2.26
Price / Book: 5.43

Profitability

EPS (TTM): -0.49000
Net Income (TTM): $-21.67M
Gross Margin: $73.4M
Return on Equity: -21.12%
Return on Assets: -16.67%

Y-mAbs Therapeutics Earnings Forecast

Key Y-mAbs Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 5 years for YMAB is 86.54%.
  • The Selling, General & Administrative Expenses for YMAB have been equal to 52.88% of Gross Profit Margin.
  • The Research & Development expenses have been 63.92% of Revenue.
  • The Interest Expense is -0.79% of Operating Income.
  • The Net Earning history of YMAB is -25.26% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 2 years.

Y-mAbs Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: YMAB
CUSIP: 984241
Website: ymabs.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 6.15
Quick Ratio: 5.47

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

YMAB Technical Analysis vs Fundamental Analysis

Sell
39
Y-mAbs Therapeutics (YMAB) is a Sell

Is Y-mAbs Therapeutics a Buy or a Sell?